Should diabetics get their liver checked? Yes: the American Diabetes Association (ADA) recommends screening adults with type 2 diabetes or prediabetes for the risk of serious liver scarring, even when liver enzymes are normal. A clinician usually begins with a calculated FIB-4 score and decides whether further tests are needed. Screening estimates risk; it does not diagnose liver disease by itself.
Key takeaways
- The ADA's Standards of Care in Diabetes—2026 recommend liver fibrosis risk screening for adults with type 2 diabetes or prediabetes, particularly with additional cardiometabolic risks.
- Normal ALT and AST results do not rule out liver disease. Feeling well is not a substitute for a screening conversation.
- FIB-4 uses age, AST, ALT, and a platelet count. Clinicians interpret it with the health history and may arrange elastography, another blood test, or specialist review.
- Bring prior reports and a complete medicine-and-supplement list. Urgent symptoms need emergency care, not a routine screening appointment.
Should People With Diabetes Get Their Liver Checked? The Quick Answer
Yes, adults with type 2 diabetes or prediabetes should discuss liver risk screening with their care team. The ADA recommends a calculated FIB-4 assessment even if liver enzyme results are normal, with particular attention to people with obesity, other cardiometabolic risk factors, or cardiovascular disease. Further testing depends on the clinician's assessment, not on a number interpreted at home. For type 1 diabetes, the ADA describes screening when additional risk factors are present rather than applying the same broad screening recommendation.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), formerly NAFLD/NASH, are related but different terms. MASLD describes liver fat with cardiometabolic risk; MASH includes inflammation and liver-cell injury. Fibrosis means scarring. The screening conversation focuses on the risk of advanced scarring and MASH-related cirrhosis, not simply whether fat is present.
The overview of diabetes and liver health explains the wider connection.
Who Should Discuss Liver Screening With Their Diabetes Team?
The ADA recommends screening adults with type 2 diabetes or prediabetes for their risk of MASH-related cirrhosis. The recommendation particularly highlights obesity, other cardiometabolic risk factors, and established cardiovascular disease. It does not say to wait until someone has pain, feels tired, or notices a change in appearance.
Body size alone should not decide whether the discussion happens. The ADA notes that MASH and cirrhosis can occur in lean people with diabetes. A clinician considers the complete history rather than using weight as a shortcut. The background article on what insulin resistance means can help explain a related risk factor without establishing whether an individual has liver disease.
Type 1 diabetes has a different screening context. The ADA describes screening when additional risk factors are present. Ask the diabetes clinician whether such factors apply and which assessment would be useful. Neither having type 1 diabetes nor lacking symptoms settles that question.
Ask whether the required blood results are already available, whether anything else is needed, and who will review the assessment. The annual diabetes tests overview helps organize broader care questions; it is not an instruction to repeat every liver test annually.
Can Fatty Liver Occur With Normal Liver Enzymes?
Yes. The ADA explicitly recommends screening even when liver enzymes are normal. Its Standards explain that a screening strategy based only on elevated enzymes would miss most people with MASH. A reassuring-looking ALT or AST result should therefore not end the conversation about fibrosis risk.
ALT and AST are blood tests used in liver assessment, as NIDDK describes in Diagnosis of NAFLD & NASH. They are not direct measurements of the amount of scarring.
The opposite situation also needs context. An elevated enzyme result does not establish MASLD or MASH on its own. The ADA advises evaluating other causes of liver disease when enzymes remain elevated for more than six months despite a low FIB-4 assessment. That is a guideline for clinical evaluation, not a reason to wait before reporting a concerning change.
Symptoms are another unreliable shortcut. NIDDK says this liver disease is often silent, even as it progresses. The companion guide to symptoms associated with fatty liver explains why fatigue or discomfort cannot confirm a diagnosis. Tell the clinician about symptoms, but do not use their presence or absence to decide that screening is unnecessary.
What Is FIB-4, and How Do Clinicians Use It?
FIB-4 is a calculated estimate that uses age and blood results for AST, ALT, and platelets. It is not a separate blood substance that the laboratory measures. The ADA uses it as an initial way to sort the probability of advanced fibrosis and identify people who may need further assessment.
The ADA describes FIB-4 values below 1.3 as indicating a lower probability of advanced fibrosis in the screening population, values at or above 1.3 as needing additional risk stratification, and values above 2.67 as high risk warranting referral. These are clinical decision categories, not diagnoses or predictions about one person. A clinician must decide how the categories apply.
Age matters. The ADA notes that FIB-4 has not been validated in adults younger than 35 and that higher cutoffs are suggested for adults aged 65 and older. This is another reason not to compare a personal result with a general table online. Even a low assessment does not replace clinical judgment.
The table below is a discussion guide, not a self-diagnosis tool:
| Item in the conversation | What it helps a clinician consider | A useful question |
|---|---|---|
| Age, AST, ALT, and platelets | The information used to calculate FIB-4 | Are the results needed for assessment available? |
| FIB-4 assessment | Whether more fibrosis testing or referral is appropriate | What does this screening step answer, and what remains uncertain? |
| Persistent enzyme changes | Whether causes beyond MASLD need evaluation | Do earlier reports change the follow-up plan? |
| Other risk factors and health history | Whether the overall picture needs additional attention | Does my history change how screening is used? |
Ask for an explanation of the assessment rather than calculating or labeling it yourself.
What Happens After the Initial Liver Risk Assessment?
The ADA recommends additional risk stratification when FIB-4 is at or above 1.3, usually with a liver stiffness measurement by transient elastography. This is an ultrasound-based scan often called FibroScan. If that assessment is unavailable, the ADA identifies the enhanced liver fibrosis blood test, or ELF, as another option.
NIDDK explains that elastography measures stiffness. It differs from a standard ultrasound that may show liver fat but cannot show inflammation or fibrosis. If someone has had an ultrasound before, it is reasonable to ask what kind of test it was and what question it answered. Do not assume that any scan has assessed all aspects of liver disease.
The ADA recommends gastroenterologist or hepatologist referral for people at higher risk of significant fibrosis. A referral is a route to more complete evaluation, not confirmation of cirrhosis. The specialist and diabetes team should explain what is known, what needs clarification, and who will coordinate the next step.
Before leaving the visit, ask how the test will be arranged, who will contact you, and what to do if no message arrives. Raise access, cost, or scheduling concerns with the care team.
How Can You Prepare for a Liver-Health Conversation?
Bring previous blood and imaging reports if you have them, along with any specialist letters. You do not need to assemble a diagnosis before the appointment. The diabetes appointment preparation checklist can help organize those records and questions.
Bring a full list of prescription medicines, over-the-counter products, and herbal or dietary supplements. Include products used occasionally, not only those taken every day. Ask a pharmacist to help check that the list is complete. Do not make medicine changes in anticipation of a test without instructions from your care team.
According to NIH LiverTox, herbal and dietary supplements, including products marketed for liver health, can themselves injure the liver and should be reviewed with a pharmacist or clinician. Marketing language is not evidence that a product is safe or suitable for liver disease.
Useful questions to write down include:
- Does my diabetes history make liver fibrosis screening appropriate?
- Have we already collected the information needed for FIB-4?
- Are age or other health factors important to the interpretation?
- Would elastography or another blood test help answer the next question?
- Who explains the results and coordinates any specialist referral?
- When should I contact the team again, and what symptoms need urgent care?
If symptoms have changed, describe their onset and pattern without assigning a cause.
How Could Liver Assessment Change the Care Plan?
Screening may lead to further evaluation, coordinated monitoring, or a conversation about lifestyle and treatment options. A clinician who identifies MASLD considers liver health alongside diabetes and cardiovascular risk rather than treating them as unrelated concerns.
The ADA recommends an interprofessional approach to lifestyle changes for adults with type 2 diabetes or prediabetes and MASLD, particularly when overweight or obesity is present. Its guidance supports a structured nutrition plan and physical activity program. NIDDK also notes that physical activity can be beneficial without weight loss and warns that rapid weight loss and malnutrition can make liver disease worse.
The guide to what may improve with fatty liver care discusses why improvement varies. Screening results do not supply a personal recovery timeline or tell someone which eating or activity plan is safe for their circumstances.
The ADA describes certain glucose-lowering and weight-management medicines, a liver-specific medicine considered with a specialist, and metabolic surgery as options for some adults. Decisions are individualized with an interprofessional team. For medicine questions, read GLP-1 medicines and fatty liver and ask your prescriber how the guidance relates to your care.
Alcohol belongs in the clinical history; for background, see our guide to alcohol and diabetes.
Which Warning Signs Need Emergency Care Instead of Screening?
Screening is for assessing risk; it is not the appropriate response to urgent symptoms. MedlinePlus Cirrhosis advises immediate emergency help for new or rapidly worsening yellowing of the skin or eyes, new or suddenly worse abdominal swelling, confusion or changes in alertness, and vomiting blood or rectal bleeding. NIDDK's Treatment for Cirrhosis also says that vomiting blood or black or bloody stools requires hospital care right away.
Seek emergency care right away or call 911 for yellowing skin or eyes that is new or worsening quickly, vomiting blood, black or bloody stools, confusion or unusual sleepiness, or a newly swelling or rapidly worsening abdomen. Do not wait for a routine appointment, a blood draw, or a screening score.
These signs do not establish the cause. Emergency clinicians need to assess them whether or not liver disease has already been diagnosed. A previous reassuring assessment should not be used to dismiss a new urgent change.
Frequently Asked Questions
Should people with type 2 diabetes get their liver checked?
Yes. The American Diabetes Association recommends screening adults with type 2 diabetes or prediabetes for the risk of MASH-related cirrhosis, even when liver enzymes are normal. A clinician generally begins with a calculated FIB-4 assessment and considers additional testing or referral when appropriate. Screening estimates risk rather than confirming a diagnosis.
What is a FIB-4 test for diabetes care?
FIB-4 is a calculated estimate using age, AST, ALT, and a platelet count. It helps clinicians assess the probability of advanced liver scarring and decide whether more testing is useful. It is not a separate laboratory measurement or a diagnosis. The clinician must consider age, health history, and other findings when interpreting it.
Can someone have fatty liver with normal liver enzymes?
Yes. The American Diabetes Association says screening should not rely on elevated liver enzymes alone because that strategy would miss most people with MASH. Normal ALT or AST results do not rule out liver disease. Discuss fibrosis risk screening with your care team rather than using normal results or the absence of symptoms as reassurance by themselves.
Does a higher FIB-4 assessment mean someone has cirrhosis?
No. FIB-4 is a risk assessment, not confirmation of cirrhosis or a way to assign a stage at home. The American Diabetes Association recommends further risk stratification for assessments needing clarification, often with elastography or an enhanced liver fibrosis blood test. A clinician or specialist explains the findings and decides what evaluation is appropriate.
How often should liver checks be repeated with diabetes?
Ask your clinician for a follow-up plan based on the complete assessment, earlier results, symptoms, and other risks. Not every liver-related test belongs on the same schedule, and a standard ultrasound does not answer the same question as elastography. Agree on who will arrange the next assessment and who will explain it.
Do people with type 1 diabetes need the same liver screening?
The American Diabetes Association describes liver screening for people with type 1 diabetes when additional risk factors are present, rather than applying the broad recommendation for adults with type 2 diabetes or prediabetes. Ask your diabetes clinician whether your history warrants assessment. Symptoms or body size alone should not be used to settle that question.
What liver-related warning signs need emergency care?
Seek emergency care right away or call 911 for new or quickly worsening yellowing skin or eyes, vomiting blood, black or bloody stools, confusion or unusual sleepiness, or new or rapidly worsening abdominal swelling. MedlinePlus and NIDDK describe these as urgent signs. Do not wait for routine testing or assume you know the cause.
References
- American Diabetes Association Professional Practice Committee. "4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026." Diabetes Care. 2026;49(Suppl. 1):S61–S88. Accessed October 2026.
- Rinella ME, et al. "A multisociety Delphi consensus statement on new fatty liver disease nomenclature." Hepatology. 2023;78(6):1966–1986.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Diagnosis of NAFLD & NASH." Accessed October 2026.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Symptoms & Causes of NAFLD & NASH." Accessed October 2026.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Treatment for NAFLD & NASH." Accessed October 2026.
- NIH LiverTox. "Herbal and Dietary Supplements." NCBI Bookshelf, NBK548441. Accessed October 2026.
- MedlinePlus Medical Encyclopedia. "Cirrhosis." Accessed October 2026.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Treatment for Cirrhosis." Accessed October 2026.
Next Steps
Ask your diabetes clinician whether liver fibrosis risk screening has been included in your care. Bring previous reports and a complete medicine-and-supplement list, and agree on who will explain the assessment, arrange any further testing, and coordinate follow-up. Seek emergency care for urgent warning signs rather than waiting for screening.
For adults with type 2 diabetes or prediabetes who want lifestyle education alongside clinical care, the Done With Diabetes™ program, a lifestyle education protocol, offers ways to organize learning about daily habits such as meals, movement, sleep, and stress. It does not diagnose or treat liver disease, interpret lab results, change medicines, or substitute for your care team.